Drugmaker AbbVie trims profit forecasts on IPR&D expenses
(Reuters) -AbbVie Inc on Wednesday lowered its full-year and first-quarter profit expectations, citing a $150 million hit from acquired in-process research and development (IPR&D) and milestone expenses.
Source: www.reuters.com
1 Min Read
(Reuters) - AbbVie Inc said on Wednesday it expects first-quarter earnings to be hit by acquired in-process research and development (IPR&D) and milestones expenses.
The company expects first-quarter adjusted earnings, including the impact of acquired IPR&D and milestones expense, to be between $2.31 per share and $2.41 per share.
Reporting by Arunima Kumar in Bengaluru; Editing by Sriraj Kalluvila
